Kailera Therapeutics Appoints Frank K. Clyburn, Jr. to Board of Directors

Strategic Insights -

Waltham, Mass.-based biopharmaceutical company Kailera Therapeutics has announced the appointment of Frank K. Clyburn, Jr. to its Board of Directors. Clyburn brings extensive experience in the pharmaceutical and healthcare industries, with a proven track record of building and scaling global business units. As Kailera continues to advance its pipeline of next-generation therapies for obesity, Clyburn's expertise is expected to drive the company's ambition to become a global leader in the field.

Key Takeaways:

  • Frank K. Clyburn, Jr. has been appointed to Kailera Therapeutics' Board of Directors, bringing over 25 years of experience in the pharmaceutical and healthcare industries.
  • Clyburn has held leadership positions at International Flavors & Fragrances Inc. (IFF), Merck & Co, Inc., and Sanofi Aventis, overseeing various business units and portfolios, including diabetes and cardiovascular medicines and vaccines.
  • Clyburn's experience in building and scaling global business units, as well as his expertise in pharmaceutical development, are expected to drive Kailera's growth and ambition to become a global leader in obesity treatment.
  • Kailera Therapeutics currently has a broad portfolio of clinical-stage injectable and oral therapies for the treatment of obesity, including the injectable dual GLP-1/GIP receptor agonist KAI-9531 (being developed in China as HRS9531).
  • Clyburn will join the board alongside Ron Renaud, President and Chief Executive Officer of Kailera, and will contribute to the company's mission to develop next-generation weight management therapies.

Statistics:

  • Kailera Therapeutics has a portfolio of 5 clinical-stage therapies for the treatment of obesity.
  • KAI-9531, a dual GLP-1/GIP receptor agonist, has been developed in China and demonstrated positive clinical trial results.
  • Kailera Therapeutics is based in Waltham, MA, and San Diego, CA, with operations in the United States and China.

Sources:

  • GlobeNewswire (2025-11-03) - "Kailera Therapeutics Announces Appointment of Frank K. Clyburn, Jr. to Board of Directors"
  • About Kailera Therapeutics website - "Company Overview"
  • COMTEX_469991844/2010 (2025-11-03 07:30:00) - GlobeNewswire press release